rss
Ann Rheum Dis 67:1437-1443 doi:10.1136/ard.2007.077891
  • Clinical and epidemiological research

Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor α and systemic immune activation

  1. N M Moutsopoulos1,
  2. G E Katsifis1,
  3. N Angelov1,
  4. R A Leakan2,
  5. V Sankar2,
  6. S Pillemer2,
  7. S M Wahl1
  1. 1
    Oral Infection and Immunity Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA
  2. 2
    Gene Therapy and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA
  1. Dr S M Wahl, Bldg 30, Room 320, 30 Convent Dr, MSC 4352, Oral Infection and Immunity Branch, NIDCR, NIH, Bethesda, MD 20892, USA; SMWahl{at}mail.nih.gov
  • Accepted 20 December 2007
  • Published Online First 15 January 2008

Abstract

Objective: To provide insight into the clinical failure of the tumour necrosis factor α (TNFα) inhibitor, etanercept, in primary Sjögren syndrome (pSS), an extensive analysis of the systemic immune profile of patients with pSS was carried out and the effect of etanercept treatment on these immune parameters monitored.

Methods: Peripheral blood mononuclear cells of patients with pSS and healthy controls were compared by flow cytometry to determine differences in distribution of specific cell populations (T cells, B cells, monocytes), and to determine their expression of activation markers (CD25, HLA-DR), TNF receptors and chemokine receptors (CXCR1, 2) before and after treatment. Systemic cytokine levels were measured by multiplex ELISA assay in plasma and in lipopolysaccharide-stimulated whole blood from healthy controls and from patients with pSS before and after etanercept treatment. Baseline cytokine levels were correlated with clinical markers of disease.

Results: Before treatment, salivary gland inflammatory focus scores did not correlate with circulating TNF levels. Furthermore, consistent with the lack of evidence of significant clinical benefit, enhanced markers of immune activation, frequency of cell subpopulations and aberrant cytokine profiles were not restored to normal levels by etanercept treatment. Remarkably, the levels of circulating TNFα were significantly increased after treatment.

Conclusion: Etanercept is an ineffective therapeutic agent in pSS consistent with the absence of suppression of TNFα and other indicators of immune activation in this patient population. These data suggest that TNFα may not be a pivotal cytokine in the pathogenesis of pSS, impelling continued molecular characterisation of disease parameters to define appropriate intervention targets.

Footnotes

  • Funding: This work was supported in part by the National Institute of Dental and Craniofacial Research.

  • Competing interests: None.

  • Ethics approval: Ethics committee approval obtained.

  • Current address of NA: Loma Linda University School of Dentistry, Department of Periodontics, Loma Linda, CA 92350, USA.